{ "ticker": "CI", "cik": "0001739940", "company": "The Cigna Group", "business_type": "health services (pharmacy benefits and health insurance)", "schema_template": "Health services: revenues split the way the company reports them (pharmacy revenues, premiums, fees and other revenues, net investment income) against pharmacy and other service costs, medical costs and other benefit expenses, SG&A and amortization of acquired intangibles; income from operations, the non-operating lines, net income, shareholders' net income and per-share figures; a balance sheet and cash flow on the printed lines; a health-insurer overlay (Cigna Healthcare medical care ratio, medical customers); and the company's own segment measures (adjusted revenues and pre-tax adjusted income from operations) for Evernorth Health Services, Cigna Healthcare, Other Operations and Corporate.", "reporting_currency": "USD", "converted_to_usd": false, "units": "actual US dollars (not millions), except per-share amounts (dollars per share), share counts (shares), medical customers (individuals), pharmacy claim volume (adjusted prescriptions) and ratios stated in percent", "units_notes_seen": { "FY2025 10-K consolidated statements of income": "(In millions, except per share amounts)", "FY2025 10-K consolidated balance sheets": "(In millions)", "FY2025 10-K consolidated statements of cash flows": "(In millions)", "FY2025 10-K consolidated statements of changes in total equity": "(In millions); dividends declared per share printed in the row caption in dollars", "FY2025 10-K earnings per share note": "(Shares in thousands, dollars in millions, except per share amounts)", "FY2025 10-K segment information note": "(In millions)", "FY2025 10-K MD&A financial highlights by segment": "(Dollars in millions, except per share amounts)", "FY2025 10-K MD&A reconciliation of shareholders' net income to adjusted income from operations": "(In millions) and (Diluted earnings per share)", "FY2025 10-K MD&A Evernorth selected financial information": "(Dollars and adjusted scripts in millions)", "FY2025 10-K MD&A Cigna Healthcare financial summary": "(Dollars in millions); medical care ratio in percent", "FY2025 10-K MD&A Cigna Healthcare medical customers": "(In thousands)", "Q3 2026 10-Q consolidated statements of income": "(In millions, except per share amounts)", "Q3 2026 10-Q consolidated balance sheets": "(In millions)", "Q3 2026 10-Q consolidated statements of cash flows": "(In millions); nine-month columns only", "Q3 2026 10-Q consolidated statements of changes in total equity": "(In millions); dividends declared per share printed in the row caption in dollars", "Q3 2026 10-Q earnings per share note (Note 5)": "(Shares in thousands, dollars in millions, except per share amounts)", "Q3 2026 10-Q segment information note (Note 15)": "(In millions)", "Q3 2026 10-Q MD&A financial highlights by segment": "(Dollars in millions, except per share amounts)", "Q3 2026 10-Q MD&A reconciliation of shareholders' net income to adjusted income from operations": "(In millions) and (Diluted earnings per share)", "Q3 2026 10-Q MD&A Evernorth selected financial information": "(Dollars and adjusted scripts in millions)", "Q3 2026 10-Q MD&A Cigna Healthcare financial summary": "(Dollars in millions); medical care ratio in percent", "Q3 2026 10-Q MD&A Cigna Healthcare medical customers": "(In thousands)" }, "adjustments": { "splits_applied": [], "adr_ratio": null, "fx": "None. The Cigna Group reports in U.S. dollars." }, "annual": [ { "label": "FY2025", "period_start": "2025-01-01", "period_end": "2025-12-31", "period_type": "fiscal year", "source_accession": "0001739940-26-000006", "fiscal_year": 2025, "income_statement": { "pharmacy_revenues": 216672000000, "premiums": 40261000000, "fees_and_other_revenues": 16921000000, "net_investment_income": 1046000000, "total_revenues": 274900000000, "pharmacy_and_other_service_costs": 214991000000, "medical_costs_and_other_benefit_expenses": 34349000000, "selling_general_and_administrative_expenses": 14617000000, "amortization_of_acquired_intangible_assets": 1743000000, "total_benefits_and_expenses": 265700000000, "income_from_operations": 9200000000, "interest_expense_and_other": -1408000000, "net_gain_loss_on_sale_of_businesses": 13000000, "net_investment_gains_losses": -24000000, "income_before_income_taxes": 7781000000, "income_taxes": 1493000000, "net_income": 6288000000, "net_income_attributable_to_noncontrolling_interests": 331000000, "net_income_attributable_to_shareholders": 5957000000, "basic_eps": 22.33, "diluted_eps": 22.18, "basic_weighted_average_shares": 266744000, "diluted_shares": 268563000 }, "balance_sheet": { "cash_and_cash_equivalents": 7676000000, "short_term_investments": 1056000000, "accounts_receivable_net": 28768000000, "inventories": 7338000000, "assets_of_businesses_held_for_sale": 0, "total_current_assets": 47814000000, "long_term_investments": 18471000000, "reinsurance_recoverables": 4103000000, "property_and_equipment": 3651000000, "goodwill": 44924000000, "other_intangible_assets": 28560000000, "separate_account_assets": 7511000000, "total_assets": 157919000000, "current_insurance_and_contractholder_liabilities": 5710000000, "pharmacy_and_other_service_costs_payable": 30333000000, "accounts_payable": 10659000000, "accrued_expenses_and_other_liabilities": 9048000000, "short_term_debt": 592000000, "liabilities_of_businesses_held_for_sale": 0, "total_current_liabilities": 56342000000, "non_current_insurance_and_contractholder_liabilities": 9938000000, "long_term_debt": 30871000000, "separate_account_liabilities": 7511000000, "total_liabilities": 116045000000, "total_shareholders_equity": 41713000000, "noncontrolling_interests": 161000000, "total_equity": 41874000000, "total_debt": 31463000000 }, "cash_flow": { "depreciation_and_amortization": 2775000000, "net_cash_provided_by_operating_activities": 9601000000, "purchases_of_property_and_equipment": -1212000000, "acquisitions_net_of_cash_acquired": -597000000, "divestitures_net_of_cash_sold": 2984000000, "net_cash_used_in_investing_activities": -4407000000, "repurchase_of_common_stock": -3621000000, "common_stock_dividends_paid": -1611000000, "net_cash_used_in_financing_activities": -6421000000, "free_cash_flow": 8389000000 }, "key_metrics": { "adjusted_revenues": 274651000000, "adjusted_income_from_operations": 8014000000, "consolidated_pre_tax_adjusted_income_from_operations": 9870000000, "adjusted_income_from_operations_per_diluted_share": 29.84, "cigna_healthcare_medical_care_ratio_percent": 84.4, "total_medical_customers": 18118000, "dividends_declared_per_share": 6.04, "debt_to_capitalization_percent": 43.0 }, "segment_results": { "evernorth_health_services": { "pharmacy_benefit_services_adjusted_revenues": 132126000000, "specialty_and_care_services_adjusted_revenues": 102827000000, "pharmacy_benefit_services_pre_tax_adjusted_income_from_operations": 3506000000, "specialty_and_care_services_pre_tax_adjusted_income_from_operations": 3715000000, "pharmacy_claim_volume_adjusted_scripts": 2222000000, "total_revenues": 234953000000, "adjusted_revenues": 234953000000, "pre_tax_adjusted_income_from_operations": 7221000000 }, "cigna_healthcare": { "total_revenues": 47412000000, "adjusted_revenues": 47163000000, "pre_tax_adjusted_income_from_operations": 4153000000 }, "other_operations": { "total_revenues": 674000000, "adjusted_revenues": 674000000, "pre_tax_adjusted_income_from_operations": 89000000 }, "corporate_and_eliminations": { "total_revenues": -8139000000, "adjusted_revenues": -8139000000, "pre_tax_adjusted_income_from_operations": -1593000000 } } }, { "label": "FY2024", "period_start": "2024-01-01", "period_end": "2024-12-31", "period_type": "fiscal year", "source_accession": "0001739940-26-000006", "fiscal_year": 2024, "income_statement": { "pharmacy_revenues": 185362000000, "premiums": 45996000000, "fees_and_other_revenues": 14790000000, "net_investment_income": 973000000, "total_revenues": 247121000000, "pharmacy_and_other_service_costs": 182509000000, "medical_costs_and_other_benefit_expenses": 38648000000, "selling_general_and_administrative_expenses": 14844000000, "amortization_of_acquired_intangible_assets": 1703000000, "total_benefits_and_expenses": 237704000000, "income_from_operations": 9417000000, "interest_expense_and_other": -1435000000, "net_gain_loss_on_sale_of_businesses": 24000000, "net_investment_gains_losses": -2737000000, "income_before_income_taxes": 5269000000, "income_taxes": 1491000000, "net_income": 3778000000, "net_income_attributable_to_noncontrolling_interests": 344000000, "net_income_attributable_to_shareholders": 3434000000, "basic_eps": 12.25, "diluted_eps": 12.12, "basic_weighted_average_shares": 280294000, "diluted_shares": 283218000 }, "balance_sheet": { "cash_and_cash_equivalents": 7550000000, "short_term_investments": 665000000, "accounts_receivable_net": 24227000000, "inventories": 6692000000, "assets_of_businesses_held_for_sale": 7004000000, "total_current_assets": 48870000000, "long_term_investments": 15128000000, "reinsurance_recoverables": 4378000000, "property_and_equipment": 3654000000, "goodwill": 44370000000, "other_intangible_assets": 29417000000, "separate_account_assets": 7278000000, "total_assets": 155881000000, "current_insurance_and_contractholder_liabilities": 5388000000, "pharmacy_and_other_service_costs_payable": 28465000000, "accounts_payable": 9294000000, "accrued_expenses_and_other_liabilities": 9387000000, "short_term_debt": 3035000000, "liabilities_of_businesses_held_for_sale": 2410000000, "total_current_liabilities": 57979000000, "non_current_insurance_and_contractholder_liabilities": 10254000000, "long_term_debt": 28937000000, "separate_account_liabilities": 7278000000, "total_liabilities": 114638000000, "total_shareholders_equity": 41033000000, "noncontrolling_interests": 210000000, "total_equity": 41243000000, "total_debt": 31972000000 }, "cash_flow": { "depreciation_and_amortization": 2775000000, "net_cash_provided_by_operating_activities": 10363000000, "purchases_of_property_and_equipment": -1406000000, "acquisitions_net_of_cash_acquired": -131000000, "divestitures_net_of_cash_sold": 521000000, "net_cash_used_in_investing_activities": -2102000000, "repurchase_of_common_stock": -7034000000, "common_stock_dividends_paid": -1567000000, "net_cash_used_in_financing_activities": -7647000000, "free_cash_flow": 8957000000 }, "key_metrics": { "adjusted_revenues": 247099000000, "adjusted_income_from_operations": 7741000000, "consolidated_pre_tax_adjusted_income_from_operations": 9533000000, "adjusted_income_from_operations_per_diluted_share": 27.33, "cigna_healthcare_medical_care_ratio_percent": 83.2, "total_medical_customers": 19147000, "dividends_declared_per_share": 5.6, "debt_to_capitalization_percent": 43.8 }, "segment_results": { "evernorth_health_services": { "pharmacy_benefit_services_adjusted_revenues": 111822000000, "specialty_and_care_services_adjusted_revenues": 90333000000, "pharmacy_benefit_services_pre_tax_adjusted_income_from_operations": 3577000000, "specialty_and_care_services_pre_tax_adjusted_income_from_operations": 3424000000, "pharmacy_claim_volume_adjusted_scripts": 2120000000, "total_revenues": 201973000000, "adjusted_revenues": 202155000000, "pre_tax_adjusted_income_from_operations": 7001000000 }, "cigna_healthcare": { "total_revenues": 53118000000, "adjusted_revenues": 52914000000, "pre_tax_adjusted_income_from_operations": 4229000000 }, "other_operations": { "total_revenues": 828000000, "adjusted_revenues": 828000000, "pre_tax_adjusted_income_from_operations": -9000000 }, "corporate_and_eliminations": { "total_revenues": -8798000000, "adjusted_revenues": -8798000000, "pre_tax_adjusted_income_from_operations": -1688000000 } } }, { "label": "FY2023", "period_start": "2023-01-01", "period_end": "2023-12-31", "period_type": "fiscal year", "source_accession": "0001739940-26-000006", "fiscal_year": 2023, "income_statement": { "pharmacy_revenues": 137243000000, "premiums": 44237000000, "fees_and_other_revenues": 12619000000, "net_investment_income": 1166000000, "total_revenues": 195265000000, "pharmacy_and_other_service_costs": 133801000000, "medical_costs_and_other_benefit_expenses": 36287000000, "selling_general_and_administrative_expenses": 14822000000, "amortization_of_acquired_intangible_assets": 1819000000, "total_benefits_and_expenses": 186729000000, "income_from_operations": 8536000000, "interest_expense_and_other": -1446000000, "net_gain_loss_on_sale_of_businesses": -1499000000, "net_investment_gains_losses": -78000000, "income_before_income_taxes": 5513000000, "income_taxes": 141000000, "net_income": 5372000000, "net_income_attributable_to_noncontrolling_interests": 208000000, "net_income_attributable_to_shareholders": 5164000000, "basic_eps": 17.57, "diluted_eps": 17.39, "basic_weighted_average_shares": 293892000, "diluted_shares": 296882000 }, "cash_flow": { "depreciation_and_amortization": 3035000000, "net_cash_provided_by_operating_activities": 11813000000, "purchases_of_property_and_equipment": -1573000000, "acquisitions_net_of_cash_acquired": -447000000, "divestitures_net_of_cash_sold": 13000000, "net_cash_used_in_investing_activities": -5174000000, "repurchase_of_common_stock": -2284000000, "common_stock_dividends_paid": -1450000000, "net_cash_used_in_financing_activities": -4294000000, "free_cash_flow": 10240000000 }, "key_metrics": { "adjusted_revenues": 195322000000, "adjusted_income_from_operations": 7448000000, "consolidated_pre_tax_adjusted_income_from_operations": 9318000000, "adjusted_income_from_operations_per_diluted_share": 25.09, "cigna_healthcare_medical_care_ratio_percent": 81.3, "total_medical_customers": 19780000, "dividends_declared_per_share": 4.92 }, "segment_results": { "evernorth_health_services": { "pharmacy_benefit_services_adjusted_revenues": 76792000000, "specialty_and_care_services_adjusted_revenues": 76707000000, "pharmacy_benefit_services_pre_tax_adjusted_income_from_operations": 3469000000, "specialty_and_care_services_pre_tax_adjusted_income_from_operations": 2973000000, "pharmacy_claim_volume_adjusted_scripts": 1585000000, "total_revenues": 153499000000, "adjusted_revenues": 153499000000, "pre_tax_adjusted_income_from_operations": 6442000000 }, "cigna_healthcare": { "total_revenues": 51148000000, "adjusted_revenues": 51205000000, "pre_tax_adjusted_income_from_operations": 4478000000 }, "other_operations": { "total_revenues": 596000000, "adjusted_revenues": 596000000, "pre_tax_adjusted_income_from_operations": 96000000 }, "corporate_and_eliminations": { "total_revenues": -9978000000, "adjusted_revenues": -9978000000, "pre_tax_adjusted_income_from_operations": -1698000000 } } } ], "quarterly": [ { "label": "Q3 FY2026", "period_start": "2026-07-01", "period_end": "2026-09-30", "period_type": "three months", "source_accession": "0001739940-26-000071", "income_statement": { "pharmacy_revenues": 58982000000, "premiums": 9885000000, "fees_and_other_revenues": 4529000000, "net_investment_income": 287000000, "total_revenues": 73683000000, "pharmacy_and_other_service_costs": 58590000000, "medical_costs_and_other_benefit_expenses": 8496000000, "selling_general_and_administrative_expenses": 3612000000, "amortization_of_acquired_intangible_assets": 589000000, "total_benefits_and_expenses": 71287000000, "income_from_operations": 2396000000, "interest_expense_and_other": -333000000, "net_gain_loss_on_sale_of_businesses": 0, "net_investment_gains_losses": 36000000, "income_before_income_taxes": 2099000000, "income_taxes": 401000000, "net_income": 1698000000, "net_income_attributable_to_noncontrolling_interests": 256000000, "net_income_attributable_to_shareholders": 1442000000, "basic_eps": 5.49, "diluted_eps": 5.47, "basic_weighted_average_shares": 262790000, "diluted_shares": 263788000 }, "balance_sheet": { "cash_and_cash_equivalents": 6186000000, "short_term_investments": 1109000000, "accounts_receivable_net": 31492000000, "inventories": 5555000000, "total_current_assets": 47232000000, "long_term_investments": 19043000000, "reinsurance_recoverables": 3729000000, "property_and_equipment": 3739000000, "goodwill": 45537000000, "other_intangible_assets": 26755000000, "separate_account_assets": 7308000000, "total_assets": 157644000000, "current_insurance_and_contractholder_liabilities": 6404000000, "pharmacy_and_other_service_costs_payable": 27368000000, "accounts_payable": 10100000000, "accrued_expenses_and_other_liabilities": 9868000000, "short_term_debt": 2293000000, "total_current_liabilities": 56033000000, "non_current_insurance_and_contractholder_liabilities": 9242000000, "long_term_debt": 28849000000, "separate_account_liabilities": 7308000000, "total_liabilities": 113922000000, "total_shareholders_equity": 43383000000, "noncontrolling_interests": 339000000, "total_equity": 43722000000, "total_debt": 31142000000 }, "key_metrics": { "adjusted_income_from_operations_per_diluted_share": 7.98, "adjusted_income_from_operations": 2104000000, "adjusted_revenues": 73793000000, "consolidated_pre_tax_adjusted_income_from_operations": 2650000000, "cigna_healthcare_medical_care_ratio_percent": 85, "total_medical_customers": 18452000, "dividends_declared_per_share": 1.56, "debt_to_capitalization_percent": 41.8 }, "segment_results": { "evernorth_health_services": { "pharmacy_benefit_services_adjusted_revenues": 37276000000, "specialty_and_care_services_adjusted_revenues": 26498000000, "pharmacy_benefit_services_pre_tax_adjusted_income_from_operations": 765000000, "specialty_and_care_services_pre_tax_adjusted_income_from_operations": 1064000000, "pharmacy_claim_volume_adjusted_scripts": 546000000, "total_revenues": 63774000000, "adjusted_revenues": 63774000000, "pre_tax_adjusted_income_from_operations": 1829000000 }, "cigna_healthcare": { "total_revenues": 11598000000, "adjusted_revenues": 11708000000, "pre_tax_adjusted_income_from_operations": 1193000000 }, "other_operations": { "total_revenues": 128000000, "adjusted_revenues": 128000000, "pre_tax_adjusted_income_from_operations": 22000000 }, "corporate_and_eliminations": { "total_revenues": -1817000000, "adjusted_revenues": -1817000000, "pre_tax_adjusted_income_from_operations": -394000000 } } }, { "label": "Q3 FY2025", "period_start": "2025-07-01", "period_end": "2025-09-30", "period_type": "three months", "source_accession": "0001739940-26-000071", "income_statement": { "pharmacy_revenues": 56054000000, "premiums": 9081000000, "fees_and_other_revenues": 4380000000, "net_investment_income": 233000000, "total_revenues": 69748000000, "pharmacy_and_other_service_costs": 55530000000, "medical_costs_and_other_benefit_expenses": 7842000000, "selling_general_and_administrative_expenses": 3362000000, "amortization_of_acquired_intangible_assets": 436000000, "total_benefits_and_expenses": 67170000000, "income_from_operations": 2578000000, "interest_expense_and_other": -347000000, "net_gain_loss_on_sale_of_businesses": 38000000, "net_investment_gains_losses": 26000000, "income_before_income_taxes": 2295000000, "income_taxes": 322000000, "net_income": 1973000000, "net_income_attributable_to_noncontrolling_interests": 105000000, "net_income_attributable_to_shareholders": 1868000000, "basic_eps": 7.02, "diluted_eps": 6.98, "basic_weighted_average_shares": 265913000, "diluted_shares": 267530000 }, "key_metrics": { "adjusted_income_from_operations_per_diluted_share": 7.83, "adjusted_income_from_operations": 2096000000, "adjusted_revenues": 69570000000, "consolidated_pre_tax_adjusted_income_from_operations": 2578000000, "cigna_healthcare_medical_care_ratio_percent": 84.8, "total_medical_customers": 18059000, "dividends_declared_per_share": 1.51 }, "segment_results": { "evernorth_health_services": { "pharmacy_benefit_services_adjusted_revenues": 34091000000, "specialty_and_care_services_adjusted_revenues": 26300000000, "pharmacy_benefit_services_pre_tax_adjusted_income_from_operations": 975000000, "specialty_and_care_services_pre_tax_adjusted_income_from_operations": 928000000, "pharmacy_claim_volume_adjusted_scripts": 558000000, "total_revenues": 60391000000, "adjusted_revenues": 60391000000, "pre_tax_adjusted_income_from_operations": 1903000000 }, "cigna_healthcare": { "total_revenues": 10933000000, "adjusted_revenues": 10755000000, "pre_tax_adjusted_income_from_operations": 1038000000 }, "other_operations": { "total_revenues": 162000000, "adjusted_revenues": 162000000, "pre_tax_adjusted_income_from_operations": 36000000 }, "corporate_and_eliminations": { "total_revenues": -1738000000, "adjusted_revenues": -1738000000, "pre_tax_adjusted_income_from_operations": -399000000 } } } ], "year_to_date": { "label": "Nine months ended September 30, 2026", "period_start": "2026-01-01", "period_end": "2026-09-30", "period_type": "nine months", "source_accession": "0001739940-26-000071", "income_statement": { "pharmacy_revenues": 170191000000, "premiums": 29556000000, "fees_and_other_revenues": 13337000000, "net_investment_income": 761000000, "total_revenues": 213845000000, "pharmacy_and_other_service_costs": 169393000000, "medical_costs_and_other_benefit_expenses": 24850000000, "selling_general_and_administrative_expenses": 10804000000, "amortization_of_acquired_intangible_assets": 1368000000, "total_benefits_and_expenses": 206415000000, "income_from_operations": 7430000000, "interest_expense_and_other": -1046000000, "net_gain_loss_on_sale_of_businesses": 17000000, "net_investment_gains_losses": 225000000, "income_before_income_taxes": 6626000000, "income_taxes": 1192000000, "net_income": 5434000000, "net_income_attributable_to_noncontrolling_interests": 678000000, "net_income_attributable_to_shareholders": 4756000000, "basic_eps": 18.09, "diluted_eps": 18.02, "basic_weighted_average_shares": 262841000, "diluted_shares": 263923000 }, "cash_flow": { "depreciation_and_amortization": 2172000000, "net_cash_provided_by_operating_activities": 3281000000, "purchases_of_property_and_equipment": -842000000, "acquisitions_net_of_cash_acquired": 0, "divestitures_net_of_cash_sold": 26000000, "net_cash_used_in_investing_activities": -2414000000, "repurchase_of_common_stock": -531000000, "common_stock_dividends_paid": -1236000000, "net_cash_used_in_financing_activities": -2376000000, "free_cash_flow": 2439000000 }, "key_metrics": { "adjusted_income_from_operations_per_diluted_share": 23.55, "adjusted_income_from_operations": 6216000000, "adjusted_revenues": 213868000000, "consolidated_pre_tax_adjusted_income_from_operations": 7803000000, "cigna_healthcare_medical_care_ratio_percent": 83.1, "dividends_declared_per_share": 4.68 }, "segment_results": { "evernorth_health_services": { "pharmacy_benefit_services_adjusted_revenues": 104774000000, "specialty_and_care_services_adjusted_revenues": 78910000000, "pharmacy_benefit_services_pre_tax_adjusted_income_from_operations": 1768000000, "specialty_and_care_services_pre_tax_adjusted_income_from_operations": 3190000000, "pharmacy_claim_volume_adjusted_scripts": 1610000000, "total_revenues": 183684000000, "adjusted_revenues": 183684000000, "pre_tax_adjusted_income_from_operations": 4958000000 }, "cigna_healthcare": { "total_revenues": 34890000000, "adjusted_revenues": 34913000000, "pre_tax_adjusted_income_from_operations": 3983000000 }, "other_operations": { "total_revenues": 379000000, "adjusted_revenues": 379000000, "pre_tax_adjusted_income_from_operations": 70000000 }, "corporate_and_eliminations": { "total_revenues": -5108000000, "adjusted_revenues": -5108000000, "pre_tax_adjusted_income_from_operations": -1208000000 } }, "prior_year_comparative": { "label": "Nine months ended September 30, 2025", "period_start": "2025-01-01", "period_end": "2025-09-30", "period_type": "nine months", "source_accession": "0001739940-26-000071", "income_statement": { "pharmacy_revenues": 158336000000, "premiums": 30973000000, "fees_and_other_revenues": 12412000000, "net_investment_income": 707000000, "total_revenues": 202428000000, "pharmacy_and_other_service_costs": 157196000000, "medical_costs_and_other_benefit_expenses": 26089000000, "selling_general_and_administrative_expenses": 11008000000, "amortization_of_acquired_intangible_assets": 1280000000, "total_benefits_and_expenses": 195573000000, "income_from_operations": 6855000000, "interest_expense_and_other": -1046000000, "net_gain_loss_on_sale_of_businesses": 79000000, "net_investment_gains_losses": 76000000, "income_before_income_taxes": 5964000000, "income_taxes": 950000000, "net_income": 5014000000, "net_income_attributable_to_noncontrolling_interests": 291000000, "net_income_attributable_to_shareholders": 4723000000, "basic_eps": 17.65, "diluted_eps": 17.52, "basic_weighted_average_shares": 267635000, "diluted_shares": 269527000 }, "cash_flow": { "depreciation_and_amortization": 2053000000, "net_cash_provided_by_operating_activities": 3452000000, "purchases_of_property_and_equipment": -890000000, "acquisitions_net_of_cash_acquired": -597000000, "divestitures_net_of_cash_sold": 2346000000, "net_cash_used_in_investing_activities": -3987000000, "repurchase_of_common_stock": -2620000000, "common_stock_dividends_paid": -1215000000, "net_cash_used_in_financing_activities": -2355000000, "free_cash_flow": 2562000000 }, "key_metrics": { "adjusted_income_from_operations_per_diluted_share": 21.76, "adjusted_income_from_operations": 5866000000, "adjusted_revenues": 202156000000, "consolidated_pre_tax_adjusted_income_from_operations": 7321000000, "cigna_healthcare_medical_care_ratio_percent": 83.3, "dividends_declared_per_share": 4.53 }, "segment_results": { "evernorth_health_services": { "pharmacy_benefit_services_adjusted_revenues": 95787000000, "specialty_and_care_services_adjusted_revenues": 76110000000, "pharmacy_benefit_services_pre_tax_adjusted_income_from_operations": 2352000000, "specialty_and_care_services_pre_tax_adjusted_income_from_operations": 2681000000, "pharmacy_claim_volume_adjusted_scripts": 1645000000, "total_revenues": 171897000000, "adjusted_revenues": 171897000000, "pre_tax_adjusted_income_from_operations": 5033000000 }, "cigna_healthcare": { "total_revenues": 36263000000, "adjusted_revenues": 35991000000, "pre_tax_adjusted_income_from_operations": 3419000000 }, "other_operations": { "total_revenues": 521000000, "adjusted_revenues": 521000000, "pre_tax_adjusted_income_from_operations": 61000000 }, "corporate_and_eliminations": { "total_revenues": -6253000000, "adjusted_revenues": -6253000000, "pre_tax_adjusted_income_from_operations": -1192000000 } } } }, "trailing_twelve_months": { "label": "Trailing twelve months ended September 30, 2026", "period_start": "2025-10-01", "period_end": "2026-09-30", "period_type": "trailing twelve months", "source_accession": "0001739940-26-000071", "income_statement": { "pharmacy_revenues_derived": 228527000000, "premiums_derived": 38844000000, "fees_and_other_revenues_derived": 17846000000, "net_investment_income_derived": 1100000000, "total_revenues_derived": 286317000000, "pharmacy_and_other_service_costs_derived": 227188000000, "medical_costs_and_other_benefit_expenses_derived": 33110000000, "selling_general_and_administrative_expenses_derived": 14413000000, "amortization_of_acquired_intangible_assets_derived": 1831000000, "total_benefits_and_expenses_derived": 276542000000, "income_from_operations_derived": 9775000000, "interest_expense_and_other_derived": -1408000000, "net_gain_loss_on_sale_of_businesses_derived": -49000000, "net_investment_gains_losses_derived": 125000000, "income_before_income_taxes_derived": 8443000000, "income_taxes_derived": 1735000000, "net_income_derived": 6708000000, "net_income_attributable_to_noncontrolling_interests_derived": 718000000, "net_income_attributable_to_shareholders_derived": 5990000000, "diluted_eps_derived": 22.68 }, "cash_flow": { "depreciation_and_amortization_derived": 2894000000, "net_cash_provided_by_operating_activities_derived": 9430000000, "purchases_of_property_and_equipment_derived": -1164000000, "acquisitions_net_of_cash_acquired_derived": 0, "divestitures_net_of_cash_sold_derived": 664000000, "net_cash_used_in_investing_activities_derived": -2834000000, "repurchase_of_common_stock_derived": -1532000000, "common_stock_dividends_paid_derived": -1632000000, "net_cash_used_in_financing_activities_derived": -6442000000, "free_cash_flow_derived": 8266000000 }, "key_metrics": { "adjusted_revenues_derived": 286363000000, "adjusted_income_from_operations_derived": 8364000000, "consolidated_pre_tax_adjusted_income_from_operations_derived": 10352000000, "adjusted_income_from_operations_per_diluted_share_derived": 31.63 } }, "notes": [ "The Cigna Group runs two main businesses: Evernorth Health Services (pharmacy benefit services, specialty pharmacy and care services) and Cigna Healthcare (medical coverage and administration for employers and individuals in the U.S. and internationally). Pharmacy revenues are about four-fifths of total revenues, so neither a manufacturer's revenue / cost of goods / gross profit frame nor a pure insurer's premiums frame describes it. This record follows the company's own income statement lines and adds the insurer measures the company reports for Cigna Healthcare (medical care ratio, medical customers) and its segment results.", "Annual figures are from the FY2025 Form 10-K (accession 0001739940-26-000006): income statements and cash flows for 2025, 2024 and 2023, and balance sheets at December 31, 2025 and 2024 (the 10-K prints two balance sheet dates, so FY2023 carries no balance sheet). Quarterly and nine-month figures are from the Form 10-Q for the quarter ended September 30, 2026 (accession 0001739940-26-000071). The 10-Q's December 31, 2025 balance sheet column agrees with the 10-K line for line.", "The 10-Q prints the three months ended September 30, 2026 and 2025 and the nine months ended on those dates; the quarters ended March 31 and June 30, 2026 are not presented in it and are not part of this record. The 10-Q's balance sheet compares September 30, 2026 with December 31, 2025, so the year-ago quarter (Q3 FY2025) carries no balance sheet.", "The 10-Q's cash flow statement covers the nine months only. No three-month cash flow figures are printed, so the quarterly entries carry no cash flow; the nine-month cash flows are in the year-to-date view.", "Signs follow the statements. Cash outflows (property and equipment purchases, acquisitions, share repurchases, dividends paid) are negative. Interest expense and other is negative. net_gain_loss_on_sale_of_businesses and net_investment_gains_losses are positive for a gain and negative for a loss; the 10-K captions these lines \"Net gain (loss) on sale of businesses\" and \"Net investment losses\" and the 10-Q \"Gain on sale of businesses\" and \"Net investment gains\", and one name is used for each across all periods.", "net_income is net income including the share attributable to noncontrolling interests. Earnings per share are struck on shareholders' net income (net_income_attributable_to_shareholders), as the company reports them. Weighted-average share counts are from the earnings per share notes, which print them in thousands.", "Derived figures: free_cash_flow is net cash provided by operating activities plus the (negative) \"Property and equipment purchases, net\" line; the company does not print a free cash flow figure. total_debt is short-term debt plus long-term debt, the definition of total debt the company uses in its debt-to-capitalization ratio. The trailing twelve months ended September 30, 2026 are FY2025 plus the nine months ended September 30, 2026 less the nine months ended September 30, 2025.", "Adjusted revenues, adjusted income from operations (after tax, in total and per diluted share) and pre-tax adjusted income from operations are the company's own measures and are not defined by U.S. generally accepted accounting principles. Adjusted income from operations is shareholders' net income excluding net investment results, amortization of acquired intangible assets and items the company designates as special items. Adjusted revenues exclude the company's share of certain investment results of joint ventures reported in Cigna Healthcare under the equity method (and, in 2024, a special item for the impairment of a dividend receivable). The GAAP figures they reconcile to are carried in the income statement lines.", "Segment figures are from the segment information notes of the 10-K and 10-Q. Segment total revenues include intersegment revenues, which are eliminated within Corporate and Eliminations, so the four columns sum to consolidated total revenues, adjusted revenues and pre-tax adjusted income from operations. The Evernorth split between Pharmacy Benefit Services and Specialty and Care Services, and pharmacy claim volume, are from the Evernorth selected financial information in MD&A. Pharmacy claim volume counts non-specialty network prescriptions filled through 90-day programs and home delivery prescriptions as three claims and all other prescriptions as one.", "The Cigna Healthcare medical care ratio is medical costs as a percentage of premiums for that segment's insured businesses, as the company computes and prints it; it cannot be recomputed from the consolidated lines. Medical customers are a point-in-time count at each period end (printed in thousands), so they appear on the quarters and fiscal years only.", "Dividends declared per share are as printed in the statements of changes in total equity. The debt-to-capitalization ratio is as stated in MD&A (41.8% at September 30, 2026; 43.0% at December 31, 2025; 43.8% at December 31, 2024).", "Comparability: on March 19, 2025 the company completed the sale of its Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies businesses to Health Care Service Corporation. Premiums and medical costs fall after that date, which is why nine-month 2026 premiums are below 2025 while third-quarter premiums rose. The 2024 net investment loss of $2.7 billion mainly reflects the impairment of VillageMD equity securities. The third quarter of 2025 included a gain on sale of businesses whose absence the company cites as the main reason third-quarter 2026 shareholders' net income fell.", "The Cigna Group has had no stock splits in the periods presented, does not have an American depositary receipt programme and reports in U.S. dollars, so no split, depositary-ratio or currency adjustment was applied." ], "uncertainties": [ "The trailing-twelve-month per-share figures (diluted EPS and adjusted income from operations per share) are the sum of the per-period figures (FY2025 plus nine months 2026 less nine months 2025), not a twelve-month total divided by a twelve-month share count, so they can differ from a recomputed figure by a few cents.", "No three-month cash flow, capital expenditure or free cash flow figure is available for the third quarter of 2026 or 2025 from these filings; quarterly cash generation can only be read from the nine-month and trailing-twelve-month views." ], "headline": { "period": "Q3 FY2026", "period_end_words": "September 30, 2026", "metrics": [ { "label": "Revenue", "format": "usd", "value": 73683000000, "text": "$73.68 billion", "exact": "$73,683,000,000", "compact": "$73.68B", "abs": "$73.68 billion", "prior_value": 69748000000, "prior": "$69.75 billion", "priorabs": "$69.75 billion", "yoy": "up 5.6%", "source": { "array": "quarterly", "field": "income_statement.total_revenues", "index": 0, "period_label": "Q3 FY2026", "period_end": "2026-09-30", "period_start": "2026-07-01", "span_days": 91, "source_accession": "0001739940-26-000071", "prior_index": 1, "prior_period_label": "Q3 FY2025", "prior_period_end": "2025-09-30", "prior_period_start": "2025-07-01", "prior_span_days": 91, "prior_source_accession": "0001739940-26-000071", "gap_days": 365 } }, { "label": "Shareholders' net income", "format": "usd", "value": 1442000000, "text": "$1.44 billion", "exact": "$1,442,000,000", "compact": "$1.44B", "abs": "$1.44 billion", "prior_value": 1868000000, "prior": "$1.87 billion", "priorabs": "$1.87 billion", "yoy": "down 22.8%", "source": { "array": "quarterly", "field": "income_statement.net_income_attributable_to_shareholders", "index": 0, "period_label": "Q3 FY2026", "period_end": "2026-09-30", "period_start": "2026-07-01", "span_days": 91, "source_accession": "0001739940-26-000071", "prior_index": 1, "prior_period_label": "Q3 FY2025", "prior_period_end": "2025-09-30", "prior_period_start": "2025-07-01", "prior_span_days": 91, "prior_source_accession": "0001739940-26-000071", "gap_days": 365 } }, { "label": "Diluted EPS", "format": "eps", "value": 5.47, "text": "$5.47", "exact": "$5.47", "compact": "$5.47", "abs": "$5.47", "prior_value": 6.98, "prior": "$6.98", "priorabs": "$6.98", "yoy": "down 21.6%", "source": { "array": "quarterly", "field": "income_statement.diluted_eps", "index": 0, "period_label": "Q3 FY2026", "period_end": "2026-09-30", "period_start": "2026-07-01", "span_days": 91, "source_accession": "0001739940-26-000071", "prior_index": 1, "prior_period_label": "Q3 FY2025", "prior_period_end": "2025-09-30", "prior_period_start": "2025-07-01", "prior_span_days": 91, "prior_source_accession": "0001739940-26-000071", "gap_days": 365 } }, { "label": "Adjusted EPS (non-GAAP)", "format": "eps", "value": 7.98, "text": "$7.98", "exact": "$7.98", "compact": "$7.98", "abs": "$7.98", "prior_value": 7.83, "prior": "$7.83", "priorabs": "$7.83", "yoy": "up 1.9%", "source": { "array": "quarterly", "field": "key_metrics.adjusted_income_from_operations_per_diluted_share", "index": 0, "period_label": "Q3 FY2026", "period_end": "2026-09-30", "period_start": "2026-07-01", "span_days": 91, "source_accession": "0001739940-26-000071", "prior_index": 1, "prior_period_label": "Q3 FY2025", "prior_period_end": "2025-09-30", "prior_period_start": "2025-07-01", "prior_span_days": 91, "prior_source_accession": "0001739940-26-000071", "gap_days": 365 } }, { "label": "Cigna Healthcare medical care ratio", "format": "pct", "value": 85, "text": "85.0%", "exact": "85.0%", "compact": "85.0%", "abs": "85.0%", "prior_value": 84.8, "prior": "84.8%", "priorabs": "84.8%", "yoy": "up 0.2 points", "source": { "array": "quarterly", "field": "key_metrics.cigna_healthcare_medical_care_ratio_percent", "index": 0, "period_label": "Q3 FY2026", "period_end": "2026-09-30", "period_start": "2026-07-01", "span_days": 91, "source_accession": "0001739940-26-000071", "prior_index": 1, "prior_period_label": "Q3 FY2025", "prior_period_end": "2025-09-30", "prior_period_start": "2025-07-01", "prior_span_days": 91, "prior_source_accession": "0001739940-26-000071", "gap_days": 365 } } ], "summary": "The Cigna Group reported total revenues of $73.68 billion for Q3 FY2026, the quarter ended September 30, 2026, up 5.6% from a year earlier. Shareholders' net income was $1.44 billion, or $5.47 per diluted share, down 22.8% from $1.87 billion, which the company attributed mainly to the absence of a gain on the sale of businesses booked in the year-ago quarter. Adjusted income from operations per diluted share, a non-GAAP measure, was $7.98, up 1.9%; higher earnings in Cigna Healthcare and in specialty and care services outweighed lower pharmacy benefit services profit, which the company attributed to large client contract renewals and strategic investments.", "qa": [ { "q": "What was The Cigna Group's revenue in Q3 FY2026?", "a": "The Cigna Group reported total revenues of $73.68 billion for Q3 FY2026, the quarter ended September 30, 2026. That is up 5.6% from $69.75 billion in the same quarter a year earlier." }, { "q": "Why did Cigna's net income fall in Q3 FY2026?", "a": "The Cigna Group's shareholders' net income was $1.44 billion in Q3 FY2026, down 22.8% from $1.87 billion a year earlier. The company attributed the decline mainly to the absence of a gain on the sale of businesses booked in the year-ago quarter." }, { "q": "What were Cigna's earnings per share in Q3 FY2026?", "a": "The Cigna Group earned $5.47 per diluted share in Q3 FY2026, down 21.6% from $6.98 a year earlier. Adjusted income from operations per diluted share, a non-GAAP measure, was $7.98, compared with $7.83." }, { "q": "What was Cigna's medical care ratio in Q3 FY2026?", "a": "The Cigna Group's Cigna Healthcare segment reported a medical care ratio of 85.0% for Q3 FY2026, up 0.2 points from 84.8% a year earlier. The ratio is medical costs as a percentage of premiums for the segment's insured businesses." } ] }, "company_details": { "Name": "Cigna Group", "Ticker": "CI", "CIK": "0001739940", "Exchange": "NYSE", "State": "Connecticut", "Incorporation": "Delaware", "SIC": "6324", "Office": "Finance", "Industry": "Hospital & Medical Service Plans" }, "next_filing": { "predicted_date": "2027-02-25", "predicted_type": "10-K" }, "fiscal_period": { "fiscal_year": 2026, "fiscal_period": "Q3", "tag": "FY26Q3", "period_end": "2026-09-30", "form": "10-Q", "accession": "0001739940-26-000071", "fiscal_year_end": "1231", "source": "facts" }, "source_filings": [ { "role": "annual", "current": false, "form": "10-K", "fiscal_year": 2025, "fiscal_period": "FY", "tag": "FY25", "period_end": "2025-12-31", "filed": "2026-02-26", "accession": "0001739940-26-000006", "url": "https://www.sec.gov/Archives/edgar/data/1739940/000173994026000006/ci-20251231.htm", "source": "reported" }, { "role": "quarterly", "current": true, "form": "10-Q", "fiscal_year": 2026, "fiscal_period": "Q3", "tag": "FY26Q3", "period_end": "2026-09-30", "filed": "2026-11-05", "accession": "0001739940-26-000071", "url": "https://www.sec.gov/Archives/edgar/data/1739940/000173994026000071/ci-20260930.htm", "source": "facts" } ], "figure_sources": { "about": "Where each figure in this file is printed in its SEC filing. This block mirrors the paths of the figures: figure_sources.annual[0].income_statement.net_income is the source of annual[0].income_statement.net_income. Each entry reads '#', and the link is documents[] + '#': it opens the filing at the line that prints that number. A figure with no entry is not printed in a tagged filing, either because it was calculated (margins, free cash flow, trailing twelve months, a quarter derived by subtraction) or because it comes from an untagged earnings release.", "documents": { "d1": "https://www.sec.gov/Archives/edgar/data/1739940/000173994026000006/ci-20251231.htm", "d2": "https://www.sec.gov/Archives/edgar/data/1739940/000173994026000071/ci-20260930.htm" }, "annual": [ { "period_end": "2025-12-31", "income_statement": { "pharmacy_revenues": "d1#f-53", "premiums": "d1#f-56", "fees_and_other_revenues": "d1#f-2787", "net_investment_income": "d1#f-62", "total_revenues": "d1#f-65", "pharmacy_and_other_service_costs": "d1#f-68", "medical_costs_and_other_benefit_expenses": "d1#f-71", "selling_general_and_administrative_expenses": "d1#f-74", "amortization_of_acquired_intangible_assets": "d1#f-77", "total_benefits_and_expenses": "d1#f-80", "income_from_operations": "d1#f-83", "interest_expense_and_other": "d1#f-86", "net_gain_loss_on_sale_of_businesses": "d1#f-89", "net_investment_gains_losses": "d1#f-92", "income_before_income_taxes": "d1#f-95", "income_taxes": "d1#f-98", "net_income": "d1#f-101", "net_income_attributable_to_noncontrolling_interests": "d1#f-104", "net_income_attributable_to_shareholders": "d1#f-107", "basic_eps": "d1#f-110", "diluted_eps": "d1#f-113", "basic_weighted_average_shares": "d1#f-625", "diluted_shares": "d1#f-639" }, "balance_sheet": { "cash_and_cash_equivalents": "d1#f-149", "short_term_investments": "d1#f-151", "accounts_receivable_net": "d1#f-153", "inventories": "d1#f-155", "total_current_assets": "d1#f-161", "long_term_investments": "d1#f-163", "reinsurance_recoverables": "d1#f-165", "property_and_equipment": "d1#f-2141", "goodwill": "d1#f-169", "other_intangible_assets": "d1#f-171", "separate_account_assets": "d1#f-175", "total_assets": "d1#f-177", "current_insurance_and_contractholder_liabilities": "d1#f-179", "pharmacy_and_other_service_costs_payable": "d1#f-181", "accounts_payable": "d1#f-183", "accrued_expenses_and_other_liabilities": "d1#f-185", "short_term_debt": "d1#f-187", "total_current_liabilities": "d1#f-191", "non_current_insurance_and_contractholder_liabilities": "d1#f-193", "long_term_debt": "d1#f-199", "separate_account_liabilities": "d1#f-201", "total_liabilities": "d1#f-203", "total_shareholders_equity": "d1#f-217", "noncontrolling_interests": "d1#f-219", "total_equity": "d1#f-221" }, "cash_flow": { "depreciation_and_amortization": "d1#f-348", "net_cash_provided_by_operating_activities": "d1#f-381", "purchases_of_property_and_equipment": "d1#f-405", "acquisitions_net_of_cash_acquired": "d1#f-408", "divestitures_net_of_cash_sold": "d1#f-411", "net_cash_used_in_investing_activities": "d1#f-420", "repurchase_of_common_stock": "d1#f-444", "common_stock_dividends_paid": "d1#f-450", "net_cash_used_in_financing_activities": "d1#f-456" }, "key_metrics": { "adjusted_revenues": "d1#f-2466", "consolidated_pre_tax_adjusted_income_from_operations": "d1#f-2481", "dividends_declared_per_share": "d1#f-323" }, "segment_results": { "evernorth_health_services": { "total_revenues": "d1#f-2452", "adjusted_revenues": "d1#f-2452", "pre_tax_adjusted_income_from_operations": "d1#f-2477" }, "cigna_healthcare": { "total_revenues": "d1#f-2453", "adjusted_revenues": "d1#f-2463", "pre_tax_adjusted_income_from_operations": "d1#f-2478" }, "other_operations": { "pre_tax_adjusted_income_from_operations": "d1#f-2479" }, "corporate_and_eliminations": { "total_revenues": "d1#f-2455", "adjusted_revenues": "d1#f-2455", "pre_tax_adjusted_income_from_operations": "d1#f-2480" } } }, { "period_end": "2024-12-31", "income_statement": { "pharmacy_revenues": "d1#f-54", "premiums": "d1#f-57", "fees_and_other_revenues": "d1#f-2788", "net_investment_income": "d1#f-63", "total_revenues": "d1#f-66", "pharmacy_and_other_service_costs": "d1#f-69", "medical_costs_and_other_benefit_expenses": "d1#f-72", "selling_general_and_administrative_expenses": "d1#f-75", "amortization_of_acquired_intangible_assets": "d1#f-78", "total_benefits_and_expenses": "d1#f-81", "income_from_operations": "d1#f-84", "interest_expense_and_other": "d1#f-87", "net_gain_loss_on_sale_of_businesses": "d1#f-90", "net_investment_gains_losses": "d1#f-93", "income_before_income_taxes": "d1#f-96", "income_taxes": "d1#f-99", "net_income": "d1#f-102", "net_income_attributable_to_noncontrolling_interests": "d1#f-105", "net_income_attributable_to_shareholders": "d1#f-108", "basic_eps": "d1#f-111", "diluted_eps": "d1#f-114", "basic_weighted_average_shares": "d1#f-627", "diluted_shares": "d1#f-642" }, "balance_sheet": { "cash_and_cash_equivalents": "d1#f-150", "short_term_investments": "d1#f-152", "accounts_receivable_net": "d1#f-154", "inventories": "d1#f-156", "assets_of_businesses_held_for_sale": "d1#f-160", "total_current_assets": "d1#f-162", "long_term_investments": "d1#f-164", "reinsurance_recoverables": "d1#f-166", "property_and_equipment": "d1#f-168", "goodwill": "d1#f-170", "other_intangible_assets": "d1#f-172", "separate_account_assets": "d1#f-176", "total_assets": "d1#f-178", "current_insurance_and_contractholder_liabilities": "d1#f-180", "pharmacy_and_other_service_costs_payable": "d1#f-182", "accounts_payable": "d1#f-184", "accrued_expenses_and_other_liabilities": "d1#f-186", "short_term_debt": "d1#f-188", "liabilities_of_businesses_held_for_sale": "d1#f-190", "total_current_liabilities": "d1#f-192", "non_current_insurance_and_contractholder_liabilities": "d1#f-194", "long_term_debt": "d1#f-200", "separate_account_liabilities": "d1#f-202", "total_liabilities": "d1#f-204", "total_shareholders_equity": "d1#f-218", "noncontrolling_interests": "d1#f-220", "total_equity": "d1#f-222" }, "cash_flow": { "depreciation_and_amortization": "d1#f-349", "net_cash_provided_by_operating_activities": "d1#f-382", "purchases_of_property_and_equipment": "d1#f-406", "acquisitions_net_of_cash_acquired": "d1#f-409", "divestitures_net_of_cash_sold": "d1#f-412", "net_cash_used_in_investing_activities": "d1#f-421", "repurchase_of_common_stock": "d1#f-445", "common_stock_dividends_paid": "d1#f-451", "net_cash_used_in_financing_activities": "d1#f-457" }, "key_metrics": { "adjusted_revenues": "d1#f-2565", "consolidated_pre_tax_adjusted_income_from_operations": "d1#f-2580", "dividends_declared_per_share": "d1#f-288" }, "segment_results": { "evernorth_health_services": { "total_revenues": "d1#f-2546", "adjusted_revenues": "d1#f-2561", "pre_tax_adjusted_income_from_operations": "d1#f-2576" }, "cigna_healthcare": { "total_revenues": "d1#f-2547", "adjusted_revenues": "d1#f-2562", "pre_tax_adjusted_income_from_operations": "d1#f-2577" }, "other_operations": { "total_revenues": "d1#f-2548", "adjusted_revenues": "d1#f-2548", "pre_tax_adjusted_income_from_operations": "d1#f-1574" }, "corporate_and_eliminations": { "total_revenues": "d1#f-2549", "adjusted_revenues": "d1#f-2549", "pre_tax_adjusted_income_from_operations": "d1#f-2579" } } }, { "period_end": "2023-12-31", "income_statement": { "pharmacy_revenues": "d1#f-55", "premiums": "d1#f-58", "fees_and_other_revenues": "d1#f-2789", "net_investment_income": "d1#f-64", "total_revenues": "d1#f-67", "pharmacy_and_other_service_costs": "d1#f-70", "medical_costs_and_other_benefit_expenses": "d1#f-73", "selling_general_and_administrative_expenses": "d1#f-76", "amortization_of_acquired_intangible_assets": "d1#f-79", "total_benefits_and_expenses": "d1#f-82", "income_from_operations": "d1#f-85", "interest_expense_and_other": "d1#f-88", "net_gain_loss_on_sale_of_businesses": "d1#f-91", "net_investment_gains_losses": "d1#f-94", "income_before_income_taxes": "d1#f-97", "income_taxes": "d1#f-100", "net_income": "d1#f-103", "net_income_attributable_to_noncontrolling_interests": "d1#f-106", "net_income_attributable_to_shareholders": "d1#f-109", "basic_eps": "d1#f-112", "diluted_eps": "d1#f-115", "basic_weighted_average_shares": "d1#f-629", "diluted_shares": "d1#f-645" }, "cash_flow": { "depreciation_and_amortization": "d1#f-350", "net_cash_provided_by_operating_activities": "d1#f-383", "purchases_of_property_and_equipment": "d1#f-407", "acquisitions_net_of_cash_acquired": "d1#f-410", "divestitures_net_of_cash_sold": "d1#f-413", "net_cash_used_in_investing_activities": "d1#f-422", "repurchase_of_common_stock": "d1#f-446", "common_stock_dividends_paid": "d1#f-452", "net_cash_used_in_financing_activities": "d1#f-458" }, "key_metrics": { "adjusted_revenues": "d1#f-2654", "consolidated_pre_tax_adjusted_income_from_operations": "d1#f-2669", "dividends_declared_per_share": "d1#f-253" }, "segment_results": { "evernorth_health_services": { "total_revenues": "d1#f-2640", "adjusted_revenues": "d1#f-2640", "pre_tax_adjusted_income_from_operations": "d1#f-2665" }, "cigna_healthcare": { "total_revenues": "d1#f-2641", "adjusted_revenues": "d1#f-2651", "pre_tax_adjusted_income_from_operations": "d1#f-2666" }, "other_operations": { "total_revenues": "d1#f-2642", "adjusted_revenues": "d1#f-2642", "pre_tax_adjusted_income_from_operations": "d1#f-2667" }, "corporate_and_eliminations": { "total_revenues": "d1#f-2643", "adjusted_revenues": "d1#f-2643", "pre_tax_adjusted_income_from_operations": "d1#f-2668" } } } ], "quarterly": [ { "period_end": "2026-09-30", "income_statement": { "pharmacy_revenues": "d2#f-30", "premiums": "d2#f-34", "fees_and_other_revenues": "d2#f-1920", "net_investment_income": "d2#f-42", "total_revenues": "d2#f-46", "pharmacy_and_other_service_costs": "d2#f-50", "medical_costs_and_other_benefit_expenses": "d2#f-54", "selling_general_and_administrative_expenses": "d2#f-58", "amortization_of_acquired_intangible_assets": "d2#f-62", "total_benefits_and_expenses": "d2#f-66", "income_from_operations": "d2#f-70", "interest_expense_and_other": "d2#f-74", "net_investment_gains_losses": "d2#f-82", "income_before_income_taxes": "d2#f-86", "income_taxes": "d2#f-90", "net_income": "d2#f-94", "net_income_attributable_to_noncontrolling_interests": "d2#f-98", "net_income_attributable_to_shareholders": "d2#f-102", "basic_eps": "d2#f-106", "diluted_eps": "d2#f-110", "basic_weighted_average_shares": "d2#f-538", "diluted_shares": "d2#f-548" }, "balance_sheet": { "cash_and_cash_equivalents": "d2#f-150", "short_term_investments": "d2#f-152", "accounts_receivable_net": "d2#f-154", "inventories": "d2#f-156", "total_current_assets": "d2#f-160", "long_term_investments": "d2#f-162", "reinsurance_recoverables": "d2#f-164", "property_and_equipment": "d2#f-166", "goodwill": "d2#f-168", "other_intangible_assets": "d2#f-170", "separate_account_assets": "d2#f-174", "total_assets": "d2#f-176", "current_insurance_and_contractholder_liabilities": "d2#f-178", "pharmacy_and_other_service_costs_payable": "d2#f-180", "accounts_payable": "d2#f-182", "accrued_expenses_and_other_liabilities": "d2#f-184", "short_term_debt": "d2#f-186", "total_current_liabilities": "d2#f-188", "non_current_insurance_and_contractholder_liabilities": "d2#f-190", "long_term_debt": "d2#f-196", "separate_account_liabilities": "d2#f-198", "total_liabilities": "d2#f-200", "total_shareholders_equity": "d2#f-214", "noncontrolling_interests": "d2#f-216", "total_equity": "d2#f-218" }, "key_metrics": { "adjusted_revenues": "d2#f-1488", "consolidated_pre_tax_adjusted_income_from_operations": "d2#f-1503", "dividends_declared_per_share": "d2#f-247" }, "segment_results": { "evernorth_health_services": { "total_revenues": "d2#f-1474", "adjusted_revenues": "d2#f-1474", "pre_tax_adjusted_income_from_operations": "d2#f-1499" }, "cigna_healthcare": { "total_revenues": "d2#f-1475", "adjusted_revenues": "d2#f-1485", "pre_tax_adjusted_income_from_operations": "d2#f-1500" }, "other_operations": { "total_revenues": "d2#f-1476", "adjusted_revenues": "d2#f-1476" }, "corporate_and_eliminations": { "total_revenues": "d2#f-1477", "adjusted_revenues": "d2#f-1477", "pre_tax_adjusted_income_from_operations": "d2#f-1502" } } }, { "period_end": "2025-09-30", "income_statement": { "pharmacy_revenues": "d2#f-31", "premiums": "d2#f-35", "fees_and_other_revenues": "d2#f-1921", "net_investment_income": "d2#f-43", "total_revenues": "d2#f-47", "pharmacy_and_other_service_costs": "d2#f-51", "medical_costs_and_other_benefit_expenses": "d2#f-55", "selling_general_and_administrative_expenses": "d2#f-59", "amortization_of_acquired_intangible_assets": "d2#f-63", "total_benefits_and_expenses": "d2#f-67", "income_from_operations": "d2#f-1592", "interest_expense_and_other": "d2#f-75", "net_gain_loss_on_sale_of_businesses": "d2#f-79", "net_investment_gains_losses": "d2#f-83", "income_before_income_taxes": "d2#f-87", "income_taxes": "d2#f-91", "net_income": "d2#f-95", "net_income_attributable_to_noncontrolling_interests": "d2#f-99", "net_income_attributable_to_shareholders": "d2#f-103", "basic_eps": "d2#f-107", "diluted_eps": "d2#f-111", "basic_weighted_average_shares": "d2#f-540", "diluted_shares": "d2#f-551" }, "key_metrics": { "adjusted_revenues": "d2#f-1577", "consolidated_pre_tax_adjusted_income_from_operations": "d2#f-1592", "dividends_declared_per_share": "d2#f-286" }, "segment_results": { "evernorth_health_services": { "total_revenues": "d2#f-1563", "adjusted_revenues": "d2#f-1563", "pre_tax_adjusted_income_from_operations": "d2#f-1588" }, "cigna_healthcare": { "total_revenues": "d2#f-1564", "adjusted_revenues": "d2#f-1574", "pre_tax_adjusted_income_from_operations": "d2#f-1589" }, "other_operations": { "total_revenues": "d2#f-1565", "adjusted_revenues": "d2#f-1565", "pre_tax_adjusted_income_from_operations": "d2#f-1590" }, "corporate_and_eliminations": { "total_revenues": "d2#f-1566", "adjusted_revenues": "d2#f-1566", "pre_tax_adjusted_income_from_operations": "d2#f-1591" } } } ], "year_to_date": { "income_statement": { "pharmacy_revenues": "d2#f-32", "premiums": "d2#f-36", "fees_and_other_revenues": "d2#f-1922", "net_investment_income": "d2#f-44", "total_revenues": "d2#f-48", "pharmacy_and_other_service_costs": "d2#f-52", "medical_costs_and_other_benefit_expenses": "d2#f-56", "selling_general_and_administrative_expenses": "d2#f-60", "amortization_of_acquired_intangible_assets": "d2#f-64", "total_benefits_and_expenses": "d2#f-68", "income_from_operations": "d2#f-72", "interest_expense_and_other": "d2#f-76", "net_gain_loss_on_sale_of_businesses": "d2#f-80", "net_investment_gains_losses": "d2#f-84", "income_before_income_taxes": "d2#f-88", "income_taxes": "d2#f-92", "net_income": "d2#f-96", "net_income_attributable_to_noncontrolling_interests": "d2#f-100", "net_income_attributable_to_shareholders": "d2#f-104", "basic_eps": "d2#f-108", "diluted_eps": "d2#f-112", "basic_weighted_average_shares": "d2#f-562", "diluted_shares": "d2#f-572" }, "cash_flow": { "depreciation_and_amortization": "d2#f-386", "net_cash_provided_by_operating_activities": "d2#f-408", "purchases_of_property_and_equipment": "d2#f-424", "divestitures_net_of_cash_sold": "d2#f-428", "net_cash_used_in_investing_activities": "d2#f-434", "repurchase_of_common_stock": "d2#f-450", "common_stock_dividends_paid": "d2#f-454", "net_cash_used_in_financing_activities": "d2#f-458" }, "key_metrics": { "adjusted_revenues": "d2#f-1671", "consolidated_pre_tax_adjusted_income_from_operations": "d2#f-1686", "dividends_declared_per_share": "d2#f-325" }, "segment_results": { "evernorth_health_services": { "total_revenues": "d2#f-1657", "adjusted_revenues": "d2#f-1657", "pre_tax_adjusted_income_from_operations": "d2#f-1682" }, "cigna_healthcare": { "total_revenues": "d2#f-1658", "adjusted_revenues": "d2#f-1668", "pre_tax_adjusted_income_from_operations": "d2#f-1683" }, "other_operations": { "total_revenues": "d2#f-1659", "adjusted_revenues": "d2#f-1659", "pre_tax_adjusted_income_from_operations": "d2#f-1431" }, "corporate_and_eliminations": { "total_revenues": "d2#f-1660", "adjusted_revenues": "d2#f-1660", "pre_tax_adjusted_income_from_operations": "d2#f-1685" } }, "prior_year_comparative": { "income_statement": { "pharmacy_revenues": "d2#f-33", "premiums": "d2#f-37", "fees_and_other_revenues": "d2#f-1923", "net_investment_income": "d2#f-45", "total_revenues": "d2#f-49", "pharmacy_and_other_service_costs": "d2#f-53", "medical_costs_and_other_benefit_expenses": "d2#f-57", "selling_general_and_administrative_expenses": "d2#f-61", "amortization_of_acquired_intangible_assets": "d2#f-65", "total_benefits_and_expenses": "d2#f-69", "income_from_operations": "d2#f-73", "interest_expense_and_other": "d2#f-77", "net_gain_loss_on_sale_of_businesses": "d2#f-81", "net_investment_gains_losses": "d2#f-85", "income_before_income_taxes": "d2#f-89", "income_taxes": "d2#f-93", "net_income": "d2#f-97", "net_income_attributable_to_noncontrolling_interests": "d2#f-101", "net_income_attributable_to_shareholders": "d2#f-105", "basic_eps": "d2#f-109", "diluted_eps": "d2#f-113", "basic_weighted_average_shares": "d2#f-564", "diluted_shares": "d2#f-575" }, "cash_flow": { "depreciation_and_amortization": "d2#f-387", "net_cash_provided_by_operating_activities": "d2#f-409", "purchases_of_property_and_equipment": "d2#f-425", "acquisitions_net_of_cash_acquired": "d2#f-427", "divestitures_net_of_cash_sold": "d2#f-429", "net_cash_used_in_investing_activities": "d2#f-435", "repurchase_of_common_stock": "d2#f-451", "common_stock_dividends_paid": "d2#f-455", "net_cash_used_in_financing_activities": "d2#f-459" }, "key_metrics": { "adjusted_revenues": "d2#f-1765", "consolidated_pre_tax_adjusted_income_from_operations": "d2#f-1780", "dividends_declared_per_share": "d2#f-364" }, "segment_results": { "evernorth_health_services": { "total_revenues": "d2#f-1751", "adjusted_revenues": "d2#f-1751", "pre_tax_adjusted_income_from_operations": "d2#f-1776" }, "cigna_healthcare": { "total_revenues": "d2#f-1752", "adjusted_revenues": "d2#f-1762", "pre_tax_adjusted_income_from_operations": "d2#f-1777" }, "other_operations": { "total_revenues": "d2#f-1753", "adjusted_revenues": "d2#f-1753", "pre_tax_adjusted_income_from_operations": "d2#f-1778" }, "corporate_and_eliminations": { "total_revenues": "d2#f-1754", "adjusted_revenues": "d2#f-1754", "pre_tax_adjusted_income_from_operations": "d2#f-1779" } } } } } }